Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count

American Journal of Hematology

Volumn 85, Issue 3, 2010, Pages 160-163

  Jacobs, Nisha L ^a   Holtan, Shernan G ^b   Porrata, Luis F ^b   Markovic, Svetomir N ^b   Tefferi, Ayalew ^b   Steensma, David P ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSOLUTE LYMPHOCYTE COUNT; ADULT; AGED; ARTICLE; CHROMOSOME 5Q; CHROMOSOME DELETION; DIAGNOSTIC TEST; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LYMPHOCYTE COUNT; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 5; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77249097478     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21618     Document Type: Article

References (22)

1. Greenberg P, Cox C, Lebeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
2. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510.
3. Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, Passamonti F, Invernizzi R, Castello A, Magrini U, Lazzarino M, Cazzola M. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009;27:754-762.
4. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 1997;79:1548-1551.
5. Alfinito F, Sica M, Luciano L, Pepa RD, Palladino C, Ferrara I, Giani U, Ruggiero G, Terrazzano G. Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes. Br J Haematol, in press.
6. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Litzow MR, Winters JL, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: A prospective study. Biol Blood Marrow Transplant 2008;14:807-816.
7. Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol 2009;84:93-97.
8. Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD, Chen D, Hanson CA, Porrata L, Tefferi A, Steensma DP. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the pre-lenalidomide era. Am J Hematol 2008;83:708-713.
9. Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B, Wang SA. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: A report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 2008;113:3331-3340.
10. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
11. Kaplan Eam P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
12. Crowley J. Survival trees by goodness of split. J Am Stat Assoc 1993;88: 457-467.
13. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-202.
14. Hokland P, Kerndrup G, Griffin JD, Ellegaard J. Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood 1986;67:898-902.
15. Meers S, van den Berghe P, Boogaerts M, Verhoef G, Delforge M. The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: A single centre study of 131 patients. Leukemia Res 2008;32:1026-1035.
16. Kordasti SY, Afzali B, Lim Z, Ingram W, Hayden J, Barber L, Matthews K, Chelliah R, Guinn B, Lombardi G, Farzaneh F, Mufti GJ. IL-17-producing CD4(1) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009;145:64-72.
17. Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, Lombardi G, Wlodarski MW, Maciejewski JP, Farzaneh F, Mufti GJ. CD41CD25high Foxp31 regulatory T-cells in myelodysplastic syndrome (MDS). Blood 2007;110:847-850.
18. Zou JX, Rollison DE, Boulware D, Chen DT, Sloand EM, Pfannes LV, Goronzy JJ, Bai F, Painter JS, Wei S, Cosgrove D, List AF, Epling-Burnette PK. Altered naive and memory CD41 T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia 2009;23: 1288-1296.
19. Xu W, Celeridad M, Sankar S, Webb DR, Bennett BL. CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet. Clin Immunol (Orlando, FL) 2008;128:392-399.
20. Gao XN, Lin J, Wang LL, Yu L. Demethylating treatment suppresses natural killer cell cytolytic activity. Mol Immunol 2009;46:2064-2070.
21. Moreau P, Mouillot G, Rousseau P, Marcou C, Dausset J, Carosella ED. HLAG gene repression is reversed by demethylation. Proc Natl Acad Sci USA 2003;100:1191-1196.
22. Yan WH, Lin A, Chen BG, Luo WD, Dai MZ, Chen XJ, Xu HH, Li BL. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med 2008;12:889-898.